Virtual Library
Start Your Search
R. Okita
Author of
-
+
P2.02 - Biology/Pathology (ID 616)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.02-028 - Prognostic Value of Cox-2 Expression Differs Depending on CD8+ T Lymphocytes and PD-L1 Expression in Resected Lung Adenocarcinoma (ID 8108)
09:30 - 09:30 | Author(s): R. Okita
- Abstract
Background:
Programmed cell death-1 ligand 1 (PD-L1), tumor infiltrating CD8-positive T lymphocytes (CD8+TILs), and cyclooxygenase-2 (Cox-2) has been used as a prognostic tool in lung adenocarcinoma.
Method:
We conducted a retrospective review of data from 170 patients who underwent pulmonary resection as the first treatment for clinical T1-2 N0 lung adenocarcinoma. We investigated the expressions of three biomarkers and EGFR mutation, and analyzed between expression levels and clinicopathological characteristics or prognosis. Then we classified tumors into four groups based on PD-L1 and CD8+TILs status, and evaluated the prognostic significance of Cox-2 expression according to tumor immune-microenvironment classification.
Result:
The high PD-L1 expression tumors showed a significantly larger number of CD8+TILs than low PD-L1 tumors, in contrast, the high Cox-2 expression tumors showed significantly fewer CD8+TILs than low Cox-2 tumors. A multivariate analysis showed that histological subtype, nodal metastasis, CD8+TILs count, and the PD-L1 expression were independent predictor of recurrence-free survival. Based on the classification of PD-L1 and CD8+TILs status, the prognosis in patients with low PD-L1 and high CD8+TILs was significantly better than other types. In patients with low PD-L1 and low CD8+TILs, the rate of EGFR mutation was significantly higher than other types and Cox-2 expression was a powerful predictor of prognosis.
Conclusion:
Clinical and pathological features in conjunction with tumor immune-microenvironment classification indicate that lung adenocarcinoma should be divided into different subgroups. The classification of PD-L1 and CD8+TILs status might predict the effect for immunocheckpoint inhibitors, EGFR tyrosine kinase inhibitors, and/or Cox-2 inhibitor.
